Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits

Elizabeth K Speliotes, Laura M Yerges-Armstrong, Jun Wu, Ruben Hernaez, Lauren J Kim, Cameron D Palmer, Vilmundur Gudnason, Gudny Eiriksdottir, Melissa E Garcia, Lenore J Launer, Michael A Nalls, Jeanne M Clark, Braxton D Mitchell, Alan R Shuldiner, Johannah L Butler, Marta Tomas, Udo Hoffmann, Shih-Jen Hwang, Joseph M Massaro, Christopher J O'Donnell, Dushyant V Sahani, Veikko Salomaa, Eric E Schadt, Stephen M Schwartz, David S Siscovick, NASH CRN, GIANT Consortium, MAGIC Investigators, Benjamin F Voight, J Jeffrey Carr, Mary F Feitosa, Tamara B Harris, Caroline S Fox, Albert V Smith, W H Linda Kao, Joel N Hirschhorn, Ingrid B Borecki, GOLD Consortium

Abstract

Nonalcoholic fatty liver disease (NAFLD) clusters in families, but the only known common genetic variants influencing risk are near PNPLA3. We sought to identify additional genetic variants influencing NAFLD using genome-wide association (GWA) analysis of computed tomography (CT) measured hepatic steatosis, a non-invasive measure of NAFLD, in large population based samples. Using variance components methods, we show that CT hepatic steatosis is heritable (∼26%-27%) in family-based Amish, Family Heart, and Framingham Heart Studies (n = 880 to 3,070). By carrying out a fixed-effects meta-analysis of genome-wide association (GWA) results between CT hepatic steatosis and ∼2.4 million imputed or genotyped SNPs in 7,176 individuals from the Old Order Amish, Age, Gene/Environment Susceptibility-Reykjavik study (AGES), Family Heart, and Framingham Heart Studies, we identify variants associated at genome-wide significant levels (p<5×10(-8)) in or near PNPLA3, NCAN, and PPP1R3B. We genotype these and 42 other top CT hepatic steatosis-associated SNPs in 592 subjects with biopsy-proven NAFLD from the NASH Clinical Research Network (NASH CRN). In comparisons with 1,405 healthy controls from the Myocardial Genetics Consortium (MIGen), we observe significant associations with histologic NAFLD at variants in or near NCAN, GCKR, LYPLAL1, and PNPLA3, but not PPP1R3B. Variants at these five loci exhibit distinct patterns of association with serum lipids, as well as glycemic and anthropometric traits. We identify common genetic variants influencing CT-assessed steatosis and risk of NAFLD. Hepatic steatosis associated variants are not uniformly associated with NASH/fibrosis or result in abnormalities in serum lipids or glycemic and anthropometric traits, suggesting genetic heterogeneity in the pathways influencing these traits.

Conflict of interest statement

Eric E. Schadt is an employee of Pacific Biosciences.

Figures

Figure 1. Study design.
Figure 1. Study design.
Meta-analysis of genome-wide association data was performed in Stage 1 across the cohorts shown. SNPs representing the best associating loci were genotyped in histology based NAFLD samples (Stage 2) from the NASH CRN matched to genome wide genotyped and imputed MIGen controls. The effects of the five NAFLD associated SNPs on NASH CRN/iCONT, metabolic phenotypes and eQTLs in liver and adipose tissue were then performed (Stage 3).
Figure 2. Genome-wide association results for GOLD…
Figure 2. Genome-wide association results for GOLD (Stage 1).
A. Manhattan plot showing the significance of association of all SNPs in the Stage 1 GOLD meta-analysis with CT hepatic steatosis. SNPs are plotted on the x-axis according to their position on each chromosome against association with CT hepatic steatosis on the y-axis (shown as -log10 p-value). SNPs that also associate with histology based NAFLD are in red, those that only associate with CT hepatic steatosis in blue. B. Quantile-quantile plot of SNPs after Stage 1 GOLD meta-analysis (black) and after removing any SNPs within 500 kb of PNPLA3, PPP1R3B, and NCAN (red).
Figure 3. Regional plots of genome-wide significant…
Figure 3. Regional plots of genome-wide significant or replicating loci of association in GOLD.
SNPs are plotted by position on chromosome against association with CT hepatic steatosis (–log10 p-value). The figures highlight the SNP taken into Stage 2 (diamond). The SNPs surrounding the most significant SNP are color-coded to reflect their LD with this SNP as in the inset (taken from pairwise R2 values from the HapMap CEU database, www.hapmap.org). Estimated recombination rates (from HapMap) are plotted in cyan to reflect the local LD structure. Genes and the direction of transcription, are noted below the plots (data from UCSC genome browser, genome.ucsc.edu). Coding SNPs in high LD with the best SNP are noted with rs number and protein change.
Figure 4. Effects on traits.
Figure 4. Effects on traits.
Direction of effect on CT fatty liver, histology NAFLD, lipid and glycemic traits of the best associating SNPs at the loci shown. Direction is shown only for significant associations. CT: CT hepatic steatosis; LDL: low density lipoprotein cholesterol; HDL: high density lipoprotein cholesterol; TG: triglycerides; HOMA-IR: homeostatic model of insulin resistance; PNPLA3: patatin-like phospholipase domain-containing protein 3 (HGNC: 18590); NCAN: neurocan (HGNC: 2465); LYPLAL1: lysophospholipase-like 1 (HGNC: 20440); GCKR: glucokinase regulatory protein (HGNC: 4196); PPP1R3B: protein phosphatase 1, regulatory subunit 3b (HGNC: 14942).

References

    1. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40:S5–10.
    1. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
    1. Harrison SA, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis. 2004;8:861–879.
    1. Fan JG, Zhu J, Li XJ, Chen L, Lu YS, et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol. 2005;20:1825–1832.
    1. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med. 2000;108:9–13.
    1. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol. 2001;96:2957–2961.
    1. Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology. 2009;136:1585–1592.
    1. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–1465.
    1. Kotronen A, Johansson LE, Johansson LM, Roos C, Westerbacka J, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia. 2009;52:1056–1060.
    1. Iwasaki M, Takada Y, Hayashi M, Minamiguchi S, Haga H, et al. Noninvasive evaluation of graft steatosis in living donor liver transplantation. Transplantation. 2004;78:1501–1505.
    1. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–750.
    1. Limanond P, Raman SS, Lassman C, Sayre J, Ghobrial RM, et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology. 2004;230:276–280.
    1. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707–713.
    1. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42:937–948.
    1. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42:579–589.
    1. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42:105–116.
    1. Zhong H, Yang X, Kaplan LM, Molony C, Schadt EE. Integrating pathway analysis and genetics of gene expression for genome-wide association studies. Am J Hum Genet. 2010;86:581–591.
    1. Yuan X, Waterworth D, Perry JR, Lim N, Song K, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet. 2008;83:520–528.
    1. Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, et al. Apoliporpotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;362:1082–1089.
    1. Price AL, Butler J, Patterson N, Capelli C, Pascali VL, et al. Discerning the ancestry of European Americans in genetic association studies. PLoS Genet. 2008;4:e236. doi: .
    1. Speliotes EK, Butler JL, Palmer CD, Voight BF, Consortium tG, et al. PNPLA3 variants specifically confer increased risk for histologic NAFLD but not metabolic disease. Hepatology. 2010;52:904–912.
    1. Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41:334–341.
    1. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 51:1209–1217.
    1. Speliotes EK, Massaro JM, Hoffmann U, Ramachandran V, Meigs JB, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: The Framingham Heart Study. Hepatology. 2010;51:1979–1987.
    1. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316:1331–1336.
    1. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161–169.
    1. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41:56–65.
    1. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40:189–197.
    1. Lindgren CM, Heid IM, Randall JC, Lamina C, Steinthorsdottir V, et al. Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet. 2009;5:e1000508. doi: .
    1. Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet. 2009;18:4081–4088.
    1. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res. 2009;50(Suppl):S237–242.
    1. Burke JE, Dennis EA. Phospholipase A2 biochemistry. Cardiovasc Drugs Ther. 2009;23:49–59.
    1. He S, McPhaul C, Li JZ, Garuti R, Kinch LN, et al. A sequence variation (I148M) in PNPlA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2009;285:6706–6715.
    1. Rauch U, Feng K, Zhou XH. Neurocan: a brain chondroitin sulfate proteoglycan. Cell Mol Life Sci. 2001;58:1842–1856.
    1. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J. 2008;414:1–18.
    1. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for genome-wide association analysis. Bioinformatics. 2007;23:1294–1296.
    1. Rampersaud E, Bielak LF, Parsa A, Shen H, Post W, et al. The association of coronary artery calcification and carotid artery intima-media thickness with distinct, traditional coronary artery disease risk factors in asymptomatic adults. Am J Epidemiol. 2008;168:1016–1023.
    1. Sorkin J, Post W, Pollin TI, O'Connell JR, Mitchell BD, et al. Exploring the genetics of longevity in the Old Order Amish. Mech Ageing Dev. 2005;126:347–350.
    1. Higgins M, Province M, Heiss G, Eckfeldt J, Ellison RC, et al. NHLBI Family Heart Study: objectives and design. Am J Epidemiol. 1996;143:1219–1228.
    1. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, et al. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology. 2005;234:35–43.
    1. Dawber T. Cambridge, MA: Harvard University Press; 1980. The Framingham Study: The Epidemiology of Atherosclerotic Disease.
    1. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979;110:281–290.
    1. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, et al. The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol. 2007;165:1328–1335.
    1. Speliotes EK, Massaro JM, Hoffmann U, Foster MC, Sahani DV, et al. Liver fat is reproducibly measured using computed tomography in the Framingham Heart Study. J Gastroenterol Hepatol. 2008;23:894–899.
    1. Chen MH, Larson MG, Hsu YH, Peloso GM, Guo CY, et al. A three-stage approach for genome-wide association studies with family data for quantitative traits. BMC Genet. 2010;11:40.
    1. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904–909.
    1. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998;62:1198–1211.
    1. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet. 2009;41:18–24.
    1. Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2009;30:88–96.
    1. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–575.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する